Bayer (FRA:BAYN) received a €123.00 ($143.02) price target from equities research analysts at Baader Bank in a report released on Monday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. Baader Bank’s price objective would suggest a potential upside of 104.97% from the company’s current price.
A number of other research firms have also recently issued reports on BAYN. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Monday. Sanford C. Bernstein set a €90.00 ($104.65) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Thursday. DZ Bank reissued a “neutral” rating on shares of Bayer in a research report on Tuesday, April 2nd. UBS Group reissued a “buy” rating and set a price objective on shares of Bayer in a research report on Wednesday, January 2nd. Finally, Deutsche Bank set a €70.00 ($81.40) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of €82.07 ($95.42).
BAYN stock opened at €60.01 ($69.78) on Monday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: Understanding Average Daily Trade Volume
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.